Neutralizing antibodies and control of HIV: Moves and countermoves

    Research output: Contribution to journalReview articlepeer-review

    21 Scopus citations


    It is now evident that powerful antibodies directed to conserved regions of HIV-1 envelope protein develop during chronic infection in some individuals and that these antibodies can neutralize a broad array of diverse isolates in vitro, so termed broadly neutralizing antibodies (bNAbs). A great deal of effort is directed internationally at understanding the ontogeny of NAbs during infection as well as in designing and testing immunogens that can elicit bNAbs in animal models and in humans. Given the parrying tactics of Env, multiple approaches, along with high-resolution structural studies, will be needed to reach a degree of understanding sufficient to design an effective vaccine. We discuss and note here some of the most important recent advances in our knowledge of how neutralizing antibodies develop in vivo, the recent discovery of extremely powerful neutralizing monoclonal antibodies isolated from natural infection, enhanced methodologies that have accelerated discoveries on both fronts, and the progress made in eliciting potent NAbs with limited breadth by vaccination.

    Original languageEnglish (US)
    Pages (from-to)64-72
    Number of pages9
    JournalCurrent HIV/AIDS Reports
    Issue number1
    StatePublished - Mar 2012


    • Envelope
    • Monoclonal antibodies
    • Neutralizing antibodies
    • Vaccines

    ASJC Scopus subject areas

    • Virology
    • Infectious Diseases


    Dive into the research topics of 'Neutralizing antibodies and control of HIV: Moves and countermoves'. Together they form a unique fingerprint.

    Cite this